Oksana Didushko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oksana Didushko has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mykyta Bielinskyi
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
4 shared publications - Serhii Herashchenko
Івано-Франківський національний медичний університет
4 shared publications - I. O. Kostitska
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
2 shared publications - N. B. Nyshchuk-Oliinyk
Івано-Франківський національний медичний університет
2 shared publications - O. O. Tkachuk-Hryhorchuk
Івано-Франківський національний медичний університет, Україна
2 shared publications - A. Y. Pavliskyi1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Open AccessAdjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
- Open Access
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 20-25
The effect of empagliflozin on fractalkine levels in patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia and low grade systemic inflammation. Among chemokines involved in diabetic inflammation, CX3CL1 (fractalkine) plays a prominent role: elevated levels are linked to insulin resistance and vascular complications. Sodium–glucose co transporter 2 (SGLT2) inhibitors, particularly empagliflozin, not only lower glucose but also exert anti inflammatory effects that may modulate CX3CL1. Objective — to evaluate the effect of empagliflozin compared with standard therapy on fractalkine (CX3CL1) and glycated hemoglobin levels in T2DM patients with varying body mass index and to determine whether the effect on CX3CL1 is mediated by changes in HbA1c. Materials and methods. A prospective study enrolled 110 adults with T2DM divided by body mass index (BMI): group I (normal weight, n=30), group II (overweight, n=40) and group III (obesity, n=40). Each group was randomised into subgroups A (standard therapy: lifestyle modification, diet, 200 min/week moderate intensity walking, metformin 850—2000 mg/day and statins) or B (standard therapy plus empagliflozin 10 mg/day for six months). HbA1c was measured by high performance liquid chromatography; CX3CL1 was quantified using a solid phase sandwich ELISA. Changes in biomarkers were analysed, percentage reductions were calculated and a linear regression (mediation analysis) evaluated whether HbA1c change mediated the effect on CX3CL1. Results. Baseline characteristics (mean age ~43 years, disease duration ~4 years) did not differ among groups. After six months, empagliflozin recipients had greater HbA1c reductions: −18.9% vs −9.2% in normal weight patients, −12.3% vs −1.6% in overweight and −7.2% vs −0.2% in obese patients (p < 0.05). Fractalkine levels declined significantly only with empagliflozin: reductions of 32.6% (group I), 23.9% (group II) and 15.3% (group III), whereas no changes were observed under standard therapy (p > 0.05). Mediation analysis demonstrated that empagliflozin therapy was associated with an additional ∼98 pg/ml reduction in CX3CL1 irrespective of HbA1c change (β=98.14; 95% CI 57.1—139.2; p=0.005), while the coefficient for ΔHbA1c was not significant (p=0.855), indicating a direct effect. Conclusions. Addition of empagliflozin to standard care yields substantial improvement in glycemic control and significant lowering of CX3CL1 across BMI categories. The identified direct effect on fractalkine suggests that the anti-inflammatory benefits of SGLT2 inhibitors extend beyond glucose lowering. These findings support the use of empagliflozin in T2DM patients, particularly those with overweight or obesity, to mitigate inflammatory and cardiorenal complications.
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 20-25
Open AccessThe effect of empagliflozin on fractalkine levels in patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia and low grade systemic inflammation. Among chemokines involved in diabetic inflammation, CX3CL1 (fractalkine) plays a prominent role: elevated levels are linked to insulin resistance and vascular complications. Sodium–glucose co transporter 2 (SGLT2) inhibitors, particularly empagliflozin, not only lower glucose but also exert anti inflammatory effects that may modulate CX3CL1. Objective — to evaluate the effect of empagliflozin compared with standard therapy on fractalkine (CX3CL1) and glycated hemoglobin levels in T2DM patients with varying body mass index and to determine whether the effect on CX3CL1 is mediated by changes in HbA1c. Materials and methods. A prospective study enrolled 110 adults with T2DM divided by body mass index (BMI): group I (normal weight, n=30), group II (overweight, n=40) and group III (obesity, n=40). Each group was randomised into subgroups A (standard therapy: lifestyle modification, diet, 200 min/week moderate intensity walking, metformin 850—2000 mg/day and statins) or B (standard therapy plus empagliflozin 10 mg/day for six months). HbA1c was measured by high performance liquid chromatography; CX3CL1 was quantified using a solid phase sandwich ELISA. Changes in biomarkers were analysed, percentage reductions were calculated and a linear regression (mediation analysis) evaluated whether HbA1c change mediated the effect on CX3CL1. Results. Baseline characteristics (mean age ~43 years, disease duration ~4 years) did not differ among groups. After six months, empagliflozin recipients had greater HbA1c reductions: −18.9% vs −9.2% in normal weight patients, −12.3% vs −1.6% in overweight and −7.2% vs −0.2% in obese patients (p < 0.05). Fractalkine levels declined significantly only with empagliflozin: reductions of 32.6% (group I), 23.9% (group II) and 15.3% (group III), whereas no changes were observed under standard therapy (p > 0.05). Mediation analysis demonstrated that empagliflozin therapy was associated with an additional ∼98 pg/ml reduction in CX3CL1 irrespective of HbA1c change (β=98.14; 95% CI 57.1—139.2; p=0.005), while the coefficient for ΔHbA1c was not significant (p=0.855), indicating a direct effect. Conclusions. Addition of empagliflozin to standard care yields substantial improvement in glycemic control and significant lowering of CX3CL1 across BMI categories. The identified direct effect on fractalkine suggests that the anti-inflammatory benefits of SGLT2 inhibitors extend beyond glucose lowering. These findings support the use of empagliflozin in T2DM patients, particularly those with overweight or obesity, to mitigate inflammatory and cardiorenal complications.
- Open Access
- 24 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (7) , 756-762
Experimental analysis of myocardial remodeling under combined metabolic and hemodynamic stress and its pharmacological correction
Background. Diabetes mellitus and heart failure are frequently coexisting conditions that synergistically accelerate pathological myocardial remodeling. Both cardiomyocyte hypertrophy and interstitial fibrosis are recognized as hallmarks of this combined pathology. Novel pharmacological interventions, including sodium-glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitors, have been shown to attenuate adverse remodeling and improve outcomes in clinical studies. However, the precise morphological correlates of these therapies at the cardiomyocyte and stromal level remain insufficiently explored in experimental models. The purpose was to investigate histological and morphometric changes of the myocardium in a rat model of streptozotocin-induced diabetes combined with isoproterenol-induced heart failure, and to evaluate the corrective effects of empagliflozin monotherapy compared to combination therapy with empagliflozin and sacubitril/valsartan. Materials and methods. Forty white random-bred male rats were divided into four groups: 1) controls; 2) untreated pathology (diabetes + heart failure); 3) empagliflozin monotherapy (10 mg/kg daily for 30 days); 4) combination therapy with empagliflozin (10 mg/kg) and sacubitril/valsartan (60 mg/kg). Myocardial samples were processed with hematoxylin-eosin and Masson’s trichrome stain. Morphometric analysis was performed using an Axioscope microscope and digital image analysis. Perimeter and cross-sectional area of cardiomyocytes and their nuclei were measured. Statistical analysis employed StatPlus and Statistica software. Results. In untreated animals (group II), we observed heterogeneous capillary congestion, stromal edema, and marked cardiomyocyte alterations: hypertrophy, atrophy, nuclear polymorphism, vacuolization, and extensive interstitial fibrosis. Morphometric indices were significantly increased compared to controls: mean cardiomyocyte area reached 351.27 ± 16.20 µm2 (vs. 217.48 ± 9.47 µm2, p < 0.01), and nuclear area — 38.19 ± 2.14 µm2 (vs. 21.06 ± 0.93 µm2, p < 0.01). Empagliflozin monotherapy (group III) partially ameliorated these changes, reducing fibrosis to small foci and lowering morphometric indices (293.89 ± 12.70 µm2 and 27.34 ± 2.18 µm2, respectively). The combination therapy (group IV) demonstrated the most pronounced effect, with near normalization of myocardial structure: interstitial edema was minimal, fibrosis was limited to thin collagen strands, and morphometric parameters approached control values (235.29 ± 7.51 µm2 and 24.63 ± 3.06 µm2). Conclusions. Empagliflozin demonstrates a significant protective effect on myocardial morphology under combined diabetic and heart failure stress. However, the addition of sacubitril/valsartan produces superior structural normalization, particularly by reducing fibrosis and edema and restoring myofibrillar organization. These findings provide morphological evidence that combination therapy may exert greater cardioprotective efficacy than monotherapy, supporting its use in complex comorbid settings.
- 24 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (7) , 756-762
Open AccessExperimental analysis of myocardial remodeling under combined metabolic and hemodynamic stress and its pharmacological correction
Background. Diabetes mellitus and heart failure are frequently coexisting conditions that synergistically accelerate pathological myocardial remodeling. Both cardiomyocyte hypertrophy and interstitial fibrosis are recognized as hallmarks of this combined pathology. Novel pharmacological interventions, including sodium-glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitors, have been shown to attenuate adverse remodeling and improve outcomes in clinical studies. However, the precise morphological correlates of these therapies at the cardiomyocyte and stromal level remain insufficiently explored in experimental models. The purpose was to investigate histological and morphometric changes of the myocardium in a rat model of streptozotocin-induced diabetes combined with isoproterenol-induced heart failure, and to evaluate the corrective effects of empagliflozin monotherapy compared to combination therapy with empagliflozin and sacubitril/valsartan. Materials and methods. Forty white random-bred male rats were divided into four groups: 1) controls; 2) untreated pathology (diabetes + heart failure); 3) empagliflozin monotherapy (10 mg/kg daily for 30 days); 4) combination therapy with empagliflozin (10 mg/kg) and sacubitril/valsartan (60 mg/kg). Myocardial samples were processed with hematoxylin-eosin and Masson’s trichrome stain. Morphometric analysis was performed using an Axioscope microscope and digital image analysis. Perimeter and cross-sectional area of cardiomyocytes and their nuclei were measured. Statistical analysis employed StatPlus and Statistica software. Results. In untreated animals (group II), we observed heterogeneous capillary congestion, stromal edema, and marked cardiomyocyte alterations: hypertrophy, atrophy, nuclear polymorphism, vacuolization, and extensive interstitial fibrosis. Morphometric indices were significantly increased compared to controls: mean cardiomyocyte area reached 351.27 ± 16.20 µm2 (vs. 217.48 ± 9.47 µm2, p < 0.01), and nuclear area — 38.19 ± 2.14 µm2 (vs. 21.06 ± 0.93 µm2, p < 0.01). Empagliflozin monotherapy (group III) partially ameliorated these changes, reducing fibrosis to small foci and lowering morphometric indices (293.89 ± 12.70 µm2 and 27.34 ± 2.18 µm2, respectively). The combination therapy (group IV) demonstrated the most pronounced effect, with near normalization of myocardial structure: interstitial edema was minimal, fibrosis was limited to thin collagen strands, and morphometric parameters approached control values (235.29 ± 7.51 µm2 and 24.63 ± 3.06 µm2). Conclusions. Empagliflozin demonstrates a significant protective effect on myocardial morphology under combined diabetic and heart failure stress. However, the addition of sacubitril/valsartan produces superior structural normalization, particularly by reducing fibrosis and edema and restoring myofibrillar organization. These findings provide morphological evidence that combination therapy may exert greater cardioprotective efficacy than monotherapy, supporting its use in complex comorbid settings.
- Open Access
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 273-277
Herbal and mineral composition for the management of thyroid dysfunction
Background. To date, herbal medicine is one of the most promising methods for comprehensive treatment of diffuse and mixed goiter. Under such conditions, it is relevant to use pharmacological preparations based on plant materials that would have a wide range of effects on thyroid function. The purpose of the study was to evaluate the effectiveness, safety and tolerability of dietary supplements containing L-tyrosine, brown algae extract (Phaeophyceae), zinc, copper, and folate, as well as dry extract of roots and rhizomes of white cinquefoil (Potentilla alba L.), dry extract of black chokeberry fruits (Aronia melanocarpa), dry extract of flowers and fruits of redhaw hawthorn (Crataegus sanguinea), sodium selenite and possibilities of their combination. Materials and methods. The study included 147 patients with nodular goiter and different thyroid functional state: 23 with diffuse goiter, euthyroidism; 24 with diffuse goiter, subclinical hypothyroidism; 22 with diffuse goiter, subclinical thyrotoxicosis; 27 with nodular goiter, euthyroidism; 25 with nodular goiter, subclinical hypothyroidism, 26 with nodular goiter, subclinical thyrotoxicosis. Results. The analysis of the use of herbal medicines showed that dietary supplements containing L-tyrosine, brown algae extract (Phaeophyceae), zinc, copper, and folate can be recommended alone or as part of a comprehensive treatment for 3 months in patients with endemic and multinodular goiter on the background of hypothyroidism and euthyroidism. In nodular goiter with hyperthyroidism and euthyroidism, it will be more effective to use herbal remedies with the inclusion of dry extract of roots and rhizomes of white cinquefoil (Potentilla alba L.), dry extract of black chokeberry fruits (Aronia melanocarpa), dry extract of flowers and fruits of redhaw hawthorn (Crataegus sanguinea), sodium selenite alone or as comprehensive treatment for 6 months. Patients with endemic and mixed goiter without thyroid dysfunction are recommended combined therapy with both herbal remedies for 3 months. Conclusions. The best effect was achieved with the combined use of both phytopreparations: in euthyroid patients with diffuse and mixed goiter, thyroid status remained normal, antibody levels were unchanged; they presented a significant decrease in volume and a tendency to decrease in the size of thyroid nodules.
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 273-277
Open AccessHerbal and mineral composition for the management of thyroid dysfunction
Background. To date, herbal medicine is one of the most promising methods for comprehensive treatment of diffuse and mixed goiter. Under such conditions, it is relevant to use pharmacological preparations based on plant materials that would have a wide range of effects on thyroid function. The purpose of the study was to evaluate the effectiveness, safety and tolerability of dietary supplements containing L-tyrosine, brown algae extract (Phaeophyceae), zinc, copper, and folate, as well as dry extract of roots and rhizomes of white cinquefoil (Potentilla alba L.), dry extract of black chokeberry fruits (Aronia melanocarpa), dry extract of flowers and fruits of redhaw hawthorn (Crataegus sanguinea), sodium selenite and possibilities of their combination. Materials and methods. The study included 147 patients with nodular goiter and different thyroid functional state: 23 with diffuse goiter, euthyroidism; 24 with diffuse goiter, subclinical hypothyroidism; 22 with diffuse goiter, subclinical thyrotoxicosis; 27 with nodular goiter, euthyroidism; 25 with nodular goiter, subclinical hypothyroidism, 26 with nodular goiter, subclinical thyrotoxicosis. Results. The analysis of the use of herbal medicines showed that dietary supplements containing L-tyrosine, brown algae extract (Phaeophyceae), zinc, copper, and folate can be recommended alone or as part of a comprehensive treatment for 3 months in patients with endemic and multinodular goiter on the background of hypothyroidism and euthyroidism. In nodular goiter with hyperthyroidism and euthyroidism, it will be more effective to use herbal remedies with the inclusion of dry extract of roots and rhizomes of white cinquefoil (Potentilla alba L.), dry extract of black chokeberry fruits (Aronia melanocarpa), dry extract of flowers and fruits of redhaw hawthorn (Crataegus sanguinea), sodium selenite alone or as comprehensive treatment for 6 months. Patients with endemic and mixed goiter without thyroid dysfunction are recommended combined therapy with both herbal remedies for 3 months. Conclusions. The best effect was achieved with the combined use of both phytopreparations: in euthyroid patients with diffuse and mixed goiter, thyroid status remained normal, antibody levels were unchanged; they presented a significant decrease in volume and a tendency to decrease in the size of thyroid nodules.
- Open Access
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 173-178
Enhanced therapy for coronary artery disease and diabetes mellitus: impact on biomarkers and clinical outcomes
Background. Cardiovascular diseases like coronary artery disease (CAD) are a major global health issue, causing millions of deaths each year. Type 2 diabetes mellitus (T2DM) worsens outcomes for those with CAD. Common risk factors suggest potential synergistic treatment approaches, including the use of quercetin, a natural flavonoid. The purpose was to examine the clinical efficacy and safety of empagliflozin and quercetin in the treatment of coronary artery disease and type 2 diabetes mellitus comorbidity in the light of their impact on parameters of inflammation. Materials and methods. A total of 128 patients diagnosed with both stable CAD and T2DM were enrolled in the study between January and December 2023. Participants were categorized into three groups. Group 1 (controls): 40 patients receiving the standard treatment protocol for CAD and T2DM. Group 2: 46 patients received standard therapy in addition to empagliflozin (10 mg daily). Group 3: 42 patients received standard therapy in addition to empagliflozin (10 mg daily) and quercetin (80 mg three times a day). Results. The results showed that age and gender were similar between the groups, indicating a balanced distribution. The study then evaluated the effects of treatment on various parameters. The baseline body mass index (BMI), glucose, glycated hemoglobin (HbA1c), soluble suppression of tumorigenicity 2 (sST2), Toll-like receptor 2 (TLR2) and TLR4 levels were comparable across all groups. After treatment, significant reductions were observed in BMI, fasting glucose, HbA1c, sST2, and TLR2/TLR4 in all groups. The most significant improvements were seen in the group that received both empagliflozin and quercetin. The findings highlight the potential benefits of these interventions in patients with coronary heart disease and type 2 diabetes mellitus. Conclusions. The addition of empagliflozin and quercetin to standard therapy appears to offer significant benefits in managing BMI, glycemic control, and inflammatory markers in patients with CAD and T2DM. The combined treatment regimen has potential to address the complex interplay of metabolic and inflammatory processes in high-risk patients. The proposed combination also showed efficacy in reducing the myocardial stress, which is shown by a decrease in serum sST2.
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 173-178
Open AccessEnhanced therapy for coronary artery disease and diabetes mellitus: impact on biomarkers and clinical outcomes
Background. Cardiovascular diseases like coronary artery disease (CAD) are a major global health issue, causing millions of deaths each year. Type 2 diabetes mellitus (T2DM) worsens outcomes for those with CAD. Common risk factors suggest potential synergistic treatment approaches, including the use of quercetin, a natural flavonoid. The purpose was to examine the clinical efficacy and safety of empagliflozin and quercetin in the treatment of coronary artery disease and type 2 diabetes mellitus comorbidity in the light of their impact on parameters of inflammation. Materials and methods. A total of 128 patients diagnosed with both stable CAD and T2DM were enrolled in the study between January and December 2023. Participants were categorized into three groups. Group 1 (controls): 40 patients receiving the standard treatment protocol for CAD and T2DM. Group 2: 46 patients received standard therapy in addition to empagliflozin (10 mg daily). Group 3: 42 patients received standard therapy in addition to empagliflozin (10 mg daily) and quercetin (80 mg three times a day). Results. The results showed that age and gender were similar between the groups, indicating a balanced distribution. The study then evaluated the effects of treatment on various parameters. The baseline body mass index (BMI), glucose, glycated hemoglobin (HbA1c), soluble suppression of tumorigenicity 2 (sST2), Toll-like receptor 2 (TLR2) and TLR4 levels were comparable across all groups. After treatment, significant reductions were observed in BMI, fasting glucose, HbA1c, sST2, and TLR2/TLR4 in all groups. The most significant improvements were seen in the group that received both empagliflozin and quercetin. The findings highlight the potential benefits of these interventions in patients with coronary heart disease and type 2 diabetes mellitus. Conclusions. The addition of empagliflozin and quercetin to standard therapy appears to offer significant benefits in managing BMI, glycemic control, and inflammatory markers in patients with CAD and T2DM. The combined treatment regimen has potential to address the complex interplay of metabolic and inflammatory processes in high-risk patients. The proposed combination also showed efficacy in reducing the myocardial stress, which is shown by a decrease in serum sST2.
- Open Access
- 29 April 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (2) , 111-117
Changes of endothelial function and oxidant status in insulin resistance and obesity under the conditions of iodine deficiency
Background. The topicality of the theme is due to the significant prevalence of cardiovascular diseases and an increase in costs for medical care, the high risk of disability, which characterizes the medical and social component of the problem. Pathological changes can be a manifestation not only of a cardiovascular disorder, but also develop as a result of other diseases, including diabetes mellitus, obesity, and thyroid pathology. One of the main mechanisms of morbidity and mortality is macrovascular complications that can occur in endothelial dysfunction and oxidative stress. The purpose of the research is to study the peculiarities of changes in the parameters of the endothelial system and oxidant status in animals with insulin resistance and obesity under conditions of adequate iodine supply and iodine deficiency. Materials and methods. Study included 75 sexually mature rats having received a high-carbohydrate, high-fat diet under conditions of adequate and limited iodine supply, followed by analysis of markers of carbohydrate metabolism, thyroid status, indices of endothelial function, lipid peroxidation and antioxidant protection. Results. The development of insulin resistance and obesity in a diet loaded with fructose and fats is accompanied by the development of endothelial dysfunction: in the blood serum, the level of endothelin-1 increases and inducible NO-synthase (iNO-synthase) is activated, in the myocardium, the activity of iNO-synthase increases compared to the data in animals who received a standard diet. The development of oxidative stress in experimental animals characterizes an increase in the content of diene conjugates and thiobarbituric acid-reactive substances in blood serum and myocardium against the background of inhibition of serum antioxidant enzymes (catalase, superoxide dismutase, ceruloplasmin, glutathione peroxidase, glutathione reductase). The degree of endothelial dysfunction and the intensity of lipoperoxidation increase with hypothyroid dysfunction against the background of iodine deficiency. Conclusions. Metabolic disorders under the conditions of insulin resistance and obesity are characterized by the development of endothelial dysfunction and oxidative stress, which are the predictors of the development of cardiovascular risks. Their intensity depends on carbohydrate and thyroid homeostasis.
- 29 April 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (2) , 111-117
Open AccessChanges of endothelial function and oxidant status in insulin resistance and obesity under the conditions of iodine deficiency
Background. The topicality of the theme is due to the significant prevalence of cardiovascular diseases and an increase in costs for medical care, the high risk of disability, which characterizes the medical and social component of the problem. Pathological changes can be a manifestation not only of a cardiovascular disorder, but also develop as a result of other diseases, including diabetes mellitus, obesity, and thyroid pathology. One of the main mechanisms of morbidity and mortality is macrovascular complications that can occur in endothelial dysfunction and oxidative stress. The purpose of the research is to study the peculiarities of changes in the parameters of the endothelial system and oxidant status in animals with insulin resistance and obesity under conditions of adequate iodine supply and iodine deficiency. Materials and methods. Study included 75 sexually mature rats having received a high-carbohydrate, high-fat diet under conditions of adequate and limited iodine supply, followed by analysis of markers of carbohydrate metabolism, thyroid status, indices of endothelial function, lipid peroxidation and antioxidant protection. Results. The development of insulin resistance and obesity in a diet loaded with fructose and fats is accompanied by the development of endothelial dysfunction: in the blood serum, the level of endothelin-1 increases and inducible NO-synthase (iNO-synthase) is activated, in the myocardium, the activity of iNO-synthase increases compared to the data in animals who received a standard diet. The development of oxidative stress in experimental animals characterizes an increase in the content of diene conjugates and thiobarbituric acid-reactive substances in blood serum and myocardium against the background of inhibition of serum antioxidant enzymes (catalase, superoxide dismutase, ceruloplasmin, glutathione peroxidase, glutathione reductase). The degree of endothelial dysfunction and the intensity of lipoperoxidation increase with hypothyroid dysfunction against the background of iodine deficiency. Conclusions. Metabolic disorders under the conditions of insulin resistance and obesity are characterized by the development of endothelial dysfunction and oxidative stress, which are the predictors of the development of cardiovascular risks. Their intensity depends on carbohydrate and thyroid homeostasis.
- Open Access
- 27 December 2022
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 18 (8) , 426-431
Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus
Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in patients with arterial hypertension and metabolic syndrome. However, there are no data about the influence of empagliflozin on leptin level; empagliflozin effectiveness against key cardiovascular risk factors in diabetic patients with normal weight and overweight has not been studied yet. The purpose of this work was to study the impact of comprehensive treatment using metformin and empagliflozin on the main cardiovascular risk factors in patients with type 2 diabetes mellitus with different body weights. Materials and methods. Ninety-seven patients with type 2 diabetes with normal weight, overweight and obesity were examined. Anthropometric indicators were taken. The parameters of carbohydrate and lipid metabolism, the level of leptin in blood serum were determined and the HOMA-IR was calculated. Results. Insulin resistance in all groups of patients was associated with abdominal obesity, hyperleptinemia (r=0.505, p<0.05; r=0.846, p<0.05; r=0.886, p<0.05 in patients of groups I–III). After a 6-month course of treatment with metformin and empagliflozin, body weight and waist circumference significantly decreased in overweight and obese patients, and no significant changes between groups were found in those with a normal body mass index. A reliable positive effect of comprehensive treatment on indicators of carbohydrate metabolism, systolic blood pressure, regardless of the patient’s weight, was noted. Under the influence of comprehensive treatment with the use of empagliflozin, the level of leptin (p<0.05) and HOMA-IR (p<0.05) also decreased significantly in patients of all groups, regardless of body mass index. Conclusions. It was found that the combined use of metformin and empagliflozin for 6 months had a reliable effect on the modified cardiovascular risk factors in patients with type 2 diabetes of different weights.
- 27 December 2022
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 18 (8) , 426-431
Open AccessCurrent possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus
Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in patients with arterial hypertension and metabolic syndrome. However, there are no data about the influence of empagliflozin on leptin level; empagliflozin effectiveness against key cardiovascular risk factors in diabetic patients with normal weight and overweight has not been studied yet. The purpose of this work was to study the impact of comprehensive treatment using metformin and empagliflozin on the main cardiovascular risk factors in patients with type 2 diabetes mellitus with different body weights. Materials and methods. Ninety-seven patients with type 2 diabetes with normal weight, overweight and obesity were examined. Anthropometric indicators were taken. The parameters of carbohydrate and lipid metabolism, the level of leptin in blood serum were determined and the HOMA-IR was calculated. Results. Insulin resistance in all groups of patients was associated with abdominal obesity, hyperleptinemia (r=0.505, p<0.05; r=0.846, p<0.05; r=0.886, p<0.05 in patients of groups I–III). After a 6-month course of treatment with metformin and empagliflozin, body weight and waist circumference significantly decreased in overweight and obese patients, and no significant changes between groups were found in those with a normal body mass index. A reliable positive effect of comprehensive treatment on indicators of carbohydrate metabolism, systolic blood pressure, regardless of the patient’s weight, was noted. Under the influence of comprehensive treatment with the use of empagliflozin, the level of leptin (p<0.05) and HOMA-IR (p<0.05) also decreased significantly in patients of all groups, regardless of body mass index. Conclusions. It was found that the combined use of metformin and empagliflozin for 6 months had a reliable effect on the modified cardiovascular risk factors in patients with type 2 diabetes of different weights.
- Open Access
- 15 March 2022
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 79 (1) , 36-42
OPTIONS OF CORRECTING INSULIN RESISTANCE AND PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
The objective of this study was to investigate the effect of empagliflozin on insulin resistance, leptin and proinflammatory cytokine levels in patients with type 2 diabetes. Materials and methods. 100 patients with type 2 diabetes with normal weight, overweight and obesity of various degrees were examined. Anthropometric indicators were taken. Levels of leptin, IL-6, CRP in blood serum were determined, HOMA index was calculated. Results. Insulin resistance in all groups of patients was associated with abdominal obesity, hyperleptinemia (r = 0.505, p < 0.05), (r = 0.846, p < 0.05), (r = 0.886, p < 0.05), (r = 0.736, p < 0.05) in patients from Group I-IV. Patients of all examined groups have shown a significant increase in IL-6 levels, compared with the control group (p < 0.05), but the level of IL-6 in patients from Group II, III and IV have been significantly higher than those from Group I (p < 0.05) and the control group (p < 0.05) and has increased along with the weight gain. Similarly, the highest indices of CRP levels have been found in patients from Group IV which proves a high pro-inflammatory activity in these patients with type 2 diabetes and obesity. After a 6-month course of treatment patients taking empagliflozin, regardless of BMI, have shown significantly decreased levels of both IL-6 (p < 0.05), and CRP (p < 0.05). Levels of leptin (p < 0.05) and HOMA index (p < 0.05) were significantly reduced in obese patients, too. Conclusions. As a result of the study, it has been established that the use of empagliflozin in the dose of 10 mg per day for 6 months has had a significant effect on anthropometric parameters and markers of insulin resistance (HOMA index, leptin) in patients with type 2 diabetes and obesity. A significant decrease in the levels of IL-6 and CRP under the influence of empagliflozin, regardless of the patient’s weight has been revealed.
- 15 March 2022
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 79 (1) , 36-42
Open AccessOPTIONS OF CORRECTING INSULIN RESISTANCE AND PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
The objective of this study was to investigate the effect of empagliflozin on insulin resistance, leptin and proinflammatory cytokine levels in patients with type 2 diabetes. Materials and methods. 100 patients with type 2 diabetes with normal weight, overweight and obesity of various degrees were examined. Anthropometric indicators were taken. Levels of leptin, IL-6, CRP in blood serum were determined, HOMA index was calculated. Results. Insulin resistance in all groups of patients was associated with abdominal obesity, hyperleptinemia (r = 0.505, p < 0.05), (r = 0.846, p < 0.05), (r = 0.886, p < 0.05), (r = 0.736, p < 0.05) in patients from Group I-IV. Patients of all examined groups have shown a significant increase in IL-6 levels, compared with the control group (p < 0.05), but the level of IL-6 in patients from Group II, III and IV have been significantly higher than those from Group I (p < 0.05) and the control group (p < 0.05) and has increased along with the weight gain. Similarly, the highest indices of CRP levels have been found in patients from Group IV which proves a high pro-inflammatory activity in these patients with type 2 diabetes and obesity. After a 6-month course of treatment patients taking empagliflozin, regardless of BMI, have shown significantly decreased levels of both IL-6 (p < 0.05), and CRP (p < 0.05). Levels of leptin (p < 0.05) and HOMA index (p < 0.05) were significantly reduced in obese patients, too. Conclusions. As a result of the study, it has been established that the use of empagliflozin in the dose of 10 mg per day for 6 months has had a significant effect on anthropometric parameters and markers of insulin resistance (HOMA index, leptin) in patients with type 2 diabetes and obesity. A significant decrease in the levels of IL-6 and CRP under the influence of empagliflozin, regardless of the patient’s weight has been revealed.
- Open Access
- 30 June 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (3) , 251-256
Сахарный диабет 2-го типа и хроническая болезнь почек: современные возможности сахароснижающей терапии
Сахарный диабет (СД) является одной из ведущих причин хронической болезни почек (ХБП). Важно, что с увеличением заболеваемости СД 2-го типа частота диабетических нефропатий также возросла. По мировым данным, более 80 % случаев заболевания терминальной стадией ХБП вызываются СД, артериальной гипертензией или их сочетанием. Эффективной стратегией уменьшения влияния диабетической нефропатии является профилактика СД 2-го типа и диагностика, а также лечение ХБП на ранних стадиях среди тех, кто уже страдает диабетом. Основную роль в снижении риска или замедлении прогрессирования диабетической болезни почек играют компенсация углеводного обмена и контроль артериального давления. Однако на выраженных стадиях ХБП компенсация углеводного обмена затруднена из-за высокого риска гипогликемии. В статье проведен обзор литературы и рекомендаций по безопасности и возможностям применения сахароснижающих средств у больных СД 2-го типа и ХБП. Препараты с доказанными кардиопротекторными и нефропротекторными свойствами — ингибиторы натрийзависимого котранспортера глюкозы 2-го типа не применяются при СКФ < 45 мл/мин/1,73 м2, агонисты глюкагоноподобного пептида 1 — при СКФ < 30 мл/мин/1,73 м2. Препараты инкретинового ряда хорошо зарекомендовали себя в качестве средств метаболического контроля в комплексной терапии пациентов с СД 2-го типа, в том числе с ХБП. Опубликованные данные свидетельствуют об эффективности и безопасности применяемых сегодня ингибиторов дипептидилпептидазы (ДПП-4) у лиц с пониженной СКФ (включая лиц, находящихся на диализе). Особое внимание уделено вилдаглиптину — селективному пероральному ингибитору ДПП-4, который благодаря благоприятному профилю безопасности успешно применяется у пациентов с СД 2-го типа пожилого возраста и хронической почечной недостаточностью (ХПН), тяжелой кардиоваскулярной патологией в анамнезе, на всех стадиях ХБП (включая уремическую), у пациентов с высоким риском развития гипогликемии. Целевые уровни гликемии пациентов с СД 2-го типа и ХБП должны быть индивидуализированными с учетом ожидаемой продолжительности жизни, функции почек, риска развития гипогликемии и сопутствующей патологии.
- 30 June 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (3) , 251-256
Open AccessСахарный диабет 2-го типа и хроническая болезнь почек: современные возможности сахароснижающей терапии
Сахарный диабет (СД) является одной из ведущих причин хронической болезни почек (ХБП). Важно, что с увеличением заболеваемости СД 2-го типа частота диабетических нефропатий также возросла. По мировым данным, более 80 % случаев заболевания терминальной стадией ХБП вызываются СД, артериальной гипертензией или их сочетанием. Эффективной стратегией уменьшения влияния диабетической нефропатии является профилактика СД 2-го типа и диагностика, а также лечение ХБП на ранних стадиях среди тех, кто уже страдает диабетом. Основную роль в снижении риска или замедлении прогрессирования диабетической болезни почек играют компенсация углеводного обмена и контроль артериального давления. Однако на выраженных стадиях ХБП компенсация углеводного обмена затруднена из-за высокого риска гипогликемии. В статье проведен обзор литературы и рекомендаций по безопасности и возможностям применения сахароснижающих средств у больных СД 2-го типа и ХБП. Препараты с доказанными кардиопротекторными и нефропротекторными свойствами — ингибиторы натрийзависимого котранспортера глюкозы 2-го типа не применяются при СКФ < 45 мл/мин/1,73 м2, агонисты глюкагоноподобного пептида 1 — при СКФ < 30 мл/мин/1,73 м2. Препараты инкретинового ряда хорошо зарекомендовали себя в качестве средств метаболического контроля в комплексной терапии пациентов с СД 2-го типа, в том числе с ХБП. Опубликованные данные свидетельствуют об эффективности и безопасности применяемых сегодня ингибиторов дипептидилпептидазы (ДПП-4) у лиц с пониженной СКФ (включая лиц, находящихся на диализе). Особое внимание уделено вилдаглиптину — селективному пероральному ингибитору ДПП-4, который благодаря благоприятному профилю безопасности успешно применяется у пациентов с СД 2-го типа пожилого возраста и хронической почечной недостаточностью (ХПН), тяжелой кардиоваскулярной патологией в анамнезе, на всех стадиях ХБП (включая уремическую), у пациентов с высоким риском развития гипогликемии. Целевые уровни гликемии пациентов с СД 2-го типа и ХБП должны быть индивидуализированными с учетом ожидаемой продолжительности жизни, функции почек, риска развития гипогликемии и сопутствующей патологии.
- Open Access
- 21 July 2017
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 13 (4) , 290-296
Дисфункція гіпоталамуса: етіологія, клініка, діагностика, лікування (методичні рекомендації)
В гіпоталамусі знаходяться ядра нейронів як вегетативної нервової, так і ендокринної системи, а також життєво важливі центри — голоду, насичення, терморегуляції, сну й бадьорості. Під впливом черепно-мозкових травм, нейроінфекцій і отруєнь така складна інтегральна система часто порушується, спричиняючи розвиток дисфункції гіпоталамуса. В підготовлених методичних рекомендаціях розглядаються питання етіології, патогенезу, клініки, діагностики та лікування дисфункції гіпоталамуса. В плані лікування основний акцент ставиться на фізіологічних підходах до нормалізації гіпоталамічних порушень. Особлива увага звертається на формування діагнозу відповідно до вимог Міжнародної класифікації хвороб 10-го перегляду, що має важливе значення для впорядкування статистичної звітності. Методичні рекомендації призначені для лікарів — ендокринологів, невропатологів, кардіологів, загальної практики, сімейних.
- 21 July 2017
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 13 (4) , 290-296
Open AccessДисфункція гіпоталамуса: етіологія, клініка, діагностика, лікування (методичні рекомендації)
В гіпоталамусі знаходяться ядра нейронів як вегетативної нервової, так і ендокринної системи, а також життєво важливі центри — голоду, насичення, терморегуляції, сну й бадьорості. Під впливом черепно-мозкових травм, нейроінфекцій і отруєнь така складна інтегральна система часто порушується, спричиняючи розвиток дисфункції гіпоталамуса. В підготовлених методичних рекомендаціях розглядаються питання етіології, патогенезу, клініки, діагностики та лікування дисфункції гіпоталамуса. В плані лікування основний акцент ставиться на фізіологічних підходах до нормалізації гіпоталамічних порушень. Особлива увага звертається на формування діагнозу відповідно до вимог Міжнародної класифікації хвороб 10-го перегляду, що має важливе значення для впорядкування статистичної звітності. Методичні рекомендації призначені для лікарів — ендокринологів, невропатологів, кардіологів, загальної практики, сімейних.